Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 16/20 | 0.54 |
| ▸ | FEN1 | P39748 | 16/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7266386 | 0.88 | ALOX5AP (0.54) | ALOX5APFEN1GPR119CASP1 | |
| SCHEMBL890655 | 0.87 | ALOX5AP (0.53) | ALOX5APFEN1GPR119CASP1 | |
| SCHEMBL1968159 | 0.86 | ALOX5AP (0.59) | ALOX5APFEN1CASP1 | |
| SCHEMBL6163597 | 0.86 | GPR119 (0.53) | ALOX5APFEN1GPR119 | |
| SCHEMBL8001453 | 0.84 | ALOX5AP (0.51) | ALOX5APFEN1GPR119 | |
| SCHEMBL7130070 | 0.82 | ALOX5AP (0.55) | ALOX5APFEN1 | |
| SCHEMBL5544964 | 0.82 | USP2 (0.48) | ALOX5APFEN1GPR119 | |
| SCHEMBL6162420 | 0.82 | RXRA (0.43) | ALOX5APFEN1 | |
| SCHEMBL6628076 | 0.81 | ALOX5AP (0.59) | ALOX5APFEN1 | |
| SCHEMBL6163373 | 0.81 | ALOX5AP (0.46) | ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732032-B2 | 3-aminocyclopentane carboxamide derivatives | MERCK PATENT GMBH (DE) | 2017-08-15 | — | — | US | claimed |
| EP-2920146-B1 | 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-28 | — | — | EP | claimed |
| US-20160264517-A1 | 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | claimed |
| EP-2920146-A1 | 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2015-09-23 | — | — | EP | claimed |
| WO-2014075754-A1 | 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-05-22 | — | — | WO | claimed |
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-9732032-B2 | 3-aminocyclopentane carboxamide derivatives | MERCK PATENT GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9629831-B2 | Benzamides and related inhibitors of factor XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| EP-2920146-B1 | 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-28 | — | — | EP | disclosed |
| US-20160264517-A1 | 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| EP-1185508-A2 | INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. (US) | 2002-03-13 | — | — | EP | disclosed |
| US-20020002183-A1 | Derivatives of a 2-((4-amidinylphenyl)-carbonylamino-1,2-phenylene)-carbonylamino-)pyridine; potent and highly selective anticoagulants; bioavailability and/or solubility; prevention and treatment of thrombosis and coagulation | MILLENNIUM PHARMACEUTICALS, INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001064642-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064643-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001038309-A1 | β-AMINO ACID-, ASPARTIC ACID- AND DIAMINOPROPIONIC-BASED INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| WO-2001019788-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-2000071508-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264517-A1 | 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | FADS1, FASN, FFAR3 | ALOX5AP 301/4885FEN1 2338/4885GPR119 144/4885 |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | ALOX5AP 2598/4885FEN1 2773/4885GPR119 2798/4885 |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | ALOX5AP 2598/4885FEN1 2773/4885GPR119 2798/4885 |
| US-20020002183-A1 | Derivatives of a 2-((4-amidinylphenyl)-carbonylamino-1,2-phenylene)-carbonylamino-)pyridine; potent and highly selective anticoagulants; bioavailability and/or solubility; prevention and treatment of thrombosis and coagulation | F2, F12, PLAT | ALOX5AP 3077/4885FEN1 3773/4885GPR119 3307/4885 |
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | TFPI, F12, TFPI2 | ALOX5AP 2598/4885FEN1 2773/4885GPR119 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.